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Rivaroxaban (XARELTO) is an oral Factor Xa inhibitor
anticoagulant. Studied in over 85,000 patients,1 it
was initially approved by the FDA in 2011 and is indicated
to treat or prevent thrombosis in a variety of clinical
settings; and when appropriately prescribed, for example in
patients with atrial ﬁbrillation, rivaroxaban has similar
anticoagulant efﬁcacy, with a lower risk of intracranial
hemorrhage, as compared to the historical standard of
warfarin.1
It is well established that anticoagulant therapy is
associated with an increased risk of hemorrhage, regardless
of the speciﬁc anticoagulant. Therefore, in the risk–beneﬁt
balance, an appropriate anticoagulation prescription occurs
in the setting of increased thrombotic risk that justiﬁes the
increased bleeding risk. This is an important consideration,
as the mitigation of the thrombotic risk attained by the
use of an anticoagulant is terminated if the anticoagulant is
stopped. Importantly, current evidence2 does not suggest a
rebound of thrombotic risk upon anticoagulation discontin-
uation; rather, the patient simply resumes the thrombotic risk
that existed prior to anticoagulant initiation, and the lack of
rebound thrombosis with rivaroxaban is supported by
longitudinal studies.2 However, in a patient at risk for a
thrombotic event, premature discontinuation of any oral
anticoagulant may increase the risk of thrombotic events,
as outlined in The United States Prescribing Information for
all of the newer non-warfarin anticoagulants (https://www.
xarelto-us.com/shared/product/xarelto/prescribing-informa
tion.pdf; http://packageinserts.bms.com/pi/pi_eliquis.pdf;KEYWORDS Rivaroxaban; Stroke; Atrial ﬁbrillation; Legal advertising
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Rivaroxaban is currently the subject of a class action
litigation. Beginning in 2014, advertising has appeared on
television, on the radio, and in print media directed toward
patients who may have experienced adverse clinical events
while on rivaroxaban. Described here are a series of serious
medical events reported in 28 submissions of 31 individual
patients to Medwatch (The FDA Safety Information and
Adverse Event Reporting System; http://www.fda.gov/
Safety/MedWatch/default.htm).Case report
Overall, based on the available data, the mean age of the
patients was 72 (range, 45–90), and 13 patients were male.
All were prescribed rivaroxaban and subsequently discon-
tinued their anticoagulant without consulting their physician
after viewing negative rivaroxaban legal advertising.
In the majority of these cases (23/31, 75%), patients
experienced a stroke or a transient ischemic neurologic
event; 2 patients had persistent residual paralysis. One
patient, a 45-year-old man receiving rivaroxaban for treat-
ment of a deep vein thrombosis, stopped the drug and died of
a subsequent pulmonary embolism, and 1 female patient,
receiving rivaroxaban for stroke prevention, stopped the
drug and died of a massive stroke (Table). All these cases
were considered to be serious medical events by the health
care professionals that submitted the reports.Discussion
There are obvious numerous and signiﬁcant limitations to
this report. These include the limited description of clinicalpen access article under the CC BY-NC-ND license
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Table Summary of clinical outcomes following abrupt rivaroxaban termination as reported to Medwatch
Case Age Sex Anticoagulant indication Consequence of stopping anticoagulant Event reported
1 NR F NVAF TIA/possible stroke September 2014
2 80 F NVAF DVT of arm November 2014
3 80 M NR Stroke December 2014
4 NR M NVAF Stroke January 2015
5 NR NR NR Stroke January 2015
6 80 F NVAF Stroke March 2015
7 NR M NR Stroke March 2015
8 55 M NVAF Cardiac thrombosis April 2015
9 NR NR NR Stroke April 2015
10 NR M VTE Cerebral and lower limb thrombosis April 2015
11 60 M NVAF Stroke April 2015
12 NR NR NR Stroke in 2 patients May 2015
13 NR F NVAF DVT June 2015
14 NR F VTE Pulmonary embolism June 2015
15 45 M VTE Death due to pulmonary embolism June 2015
16 90 M NVAF Stroke June 2015
17 NR NR NR Stroke in 3 patients June 2015
18 NR NR NR Thrombosis June 2015
19 69 F NVAF TIA July 2015
20 NR F NVAF Stroke August 2015
21 NR NR NVAF Stroke September 2015
22 NR F NVAF Death following stroke September 2015
23 NR M VTE Thrombosis September 2015
24 NR NR NR Stroke October 2015
25 NR M AF Stroke November 2015
26 70 M NR Stroke November 2015
27 90 M AF Cardiomyopathy/TIA December 2015
28 NR M AF Stroke December 2015
AF ¼ atrial ﬁbrillation; DVT ¼ deep vein thrombosis; NR ¼ not reported; NVAF ¼ nonvalvular atrial ﬁbrillation; TIA ¼ transient ischemic attack; VTE ¼
venous thromboembolism.
KEY TEACHING POINTS
 Novel oral anticoagulants provide a new treatment
option for a variety of thrombotic conditions,
including nonvalvular atrial ﬁbrillation.
 These drugs have rapid onsets and short half-lives
and should not be prematurely discontinued.
 Legal advertising concerning XARELTO
(rivaroxaban) has resulted in some patients
stopping XARELTO therapy and experiencing
adverse clinical events, such as stroke.
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submissions, such as prior medical history, clinical risk
(eg, CHADS2 score), the lack of ability to follow up on
an individual case basis, the potential for bias in the reporting
mechanism that cannot be controlled, and an unknown
denominator of the “at-risk” population. Further, it is not
known how many patients abruptly ceased rivaroxaban and
did not experience a clinical event, nor is it known howmanypatients ceased their anticoagulant and suffered an adverse
event that was not reported. Finally, while the language in
these forms clearly states that patients viewed legal advertis-
ing and stopped their rivaroxaban, this cannot be deﬁnitively
known. However, it is clear that some patients are intimi-
dated enough by the ongoing legal campaign to stop their
anticoagulant, and thus suffer an adverse event.
These cases serve to highlight the importance of following
anticoagulant prescribing information, and that physicians
should emphasize that patients should not stop anticoagulants
without medical consultation. Continued partnership between
drug manufacturers, physicians, regulators, and patients is
necessary to provide sufﬁcient education to ensure that these
important medical events do not occur.3References
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